Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ribonucleoprotein antibody ATRC-101

An engineered, human immunoglobulin (Ig) G1 monoclonal antibody directed against a ribonucleoprotein (RNP) complex, with potential immunostimulating and antineoplastic activities. Upon administration, anti-RNP antibody ATRC-101 targets and binds to its RNP complex antigen on tumor cells. This may activate the innate immune system, change the local tumor microenvironment (TME) and promote T-cell-mediated killing of tumor cells. The tumor-restricted RNP complex is expressed in a variety of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-RNP antibody ATRC-101
Code name:	ATRC 101 ATRC-101 ATRC101

anti-ribonucleoprotein antibody ATRC-101

Search NCI's Drug Dictionary